Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis.

[1]  A. Kronbichler,et al.  Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022. , 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  M. González-Gay,et al.  Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. , 2021, Clinical and Experimental Rheumatology.

[3]  B. Rovin,et al.  B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial , 2021, Annals of the Rheumatic Diseases.

[4]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[5]  A. Gabrielli,et al.  Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. , 2021, Journal of autoimmunity.

[6]  E. Deeks.  Anifrolumab: First Approval , 2021, Drugs.

[7]  Duqun Chen,et al.  Long-term renal outcomes of mesangial proliferative lupus nephritis in Chinese patients , 2021, Clinical Rheumatology.

[8]  B. Rovin,et al.  A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. , 2021, Kidney international.

[9]  S. Prahalad,et al.  Predictors for early readmission in patients hospitalized with new onset pediatric lupus nephritis , 2021, Lupus.

[10]  F. Houssiau,et al.  From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? , 2021, Annals of the Rheumatic Diseases.

[11]  A. Mackensen,et al.  CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. , 2021, The New England journal of medicine.

[12]  Bin Huang,et al.  International Consensus for the Dosing of Corticosteroids in Childhood‐Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis , 2021, Arthritis & rheumatology.

[13]  M. Khamashta,et al.  10 Years of belimumab experience: What have we learnt? , 2021, Lupus.

[14]  J. Ingelfinger.  Hematuria in Adults. , 2021, The New England journal of medicine.

[15]  J. Rodelo,et al.  Kidney transplantation outcomes in lupus nephritis: A 37-year single-center experience from Latin America , 2021, Lupus.

[16]  E. Smitherman,et al.  Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort , 2021, Lupus.

[17]  E. Bonfá,et al.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus , 2021, Pediatric Drugs.

[18]  Mimi Kim,et al.  Prescribing Patterns of Hydroxychloroquine and Glucocorticoids Among Lupus Patients After New‐Onset End‐Stage Renal Disease , 2021, Arthritis care & research.

[19]  B. Rovin,et al.  Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial , 2021, The Lancet.

[20]  B. Goilav,et al.  Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE , 2021, Pediatric Rheumatology.

[21]  L. Tuta,et al.  Advances in Lupus Nephritis Pathogenesis: From Bench to Bedside , 2021, International journal of molecular sciences.

[22]  F. Ciccia,et al.  Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study , 2021, Lupus.

[23]  C. Hedrich,et al.  Systemic Lupus Erythematosus in Children and Young People , 2021, Current Rheumatology Reports.

[24]  T. van Gelder,et al.  Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  B. Rovin,et al.  Induction and maintenance therapy of lupus nephritis: an obituary. , 2021, Kidney international.

[26]  J. Pego-Reigosa,et al.  Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis , 2021, International journal of molecular sciences.

[27]  E. Soriano,et al.  Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL) , 2020, RMD open.

[28]  A. Bomback,et al.  Belimumab in Lupus Nephritis: New Trial Results Arrive During an Exciting Time for Therapeutics. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  A. Schwarting,et al.  Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies , 2020, Rheumatology and Therapy.

[30]  E. Morales,et al.  Update on Lupus Nephritis: Looking for a New Vision , 2020, Nephron.

[31]  D. de Zeeuw,et al.  New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. , 2020, Kidney international.

[32]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[33]  B. Kasiske,et al.  Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data , 2020, Clinical transplantation.

[34]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[35]  B. Rovin,et al.  Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. , 2020, The New England journal of medicine.

[36]  Andreas Radbruch,et al.  Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. , 2020, The New England journal of medicine.

[37]  B. Goilav,et al.  Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease , 2020, BMC Nephrology.

[38]  B. Diamond,et al.  Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis , 2020, Arthritis & rheumatology.

[39]  S. Marks,et al.  Kidney outcomes for children with lupus nephritis , 2020, Pediatric Nephrology.

[40]  D. Jayne,et al.  Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations , 2020, RMD Open.

[41]  T. Rabelink,et al.  Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  C. Mok,et al.  Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[43]  C. Fiehn,et al.  Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review , 2020, Zeitschrift für Rheumatologie.

[44]  E. Frangou,et al.  2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[45]  B. Rovin,et al.  Update on Lupus Nephritis: Core Curriculum 2020. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  J. Radhakrishnan,et al.  The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[47]  H. Anders,et al.  Lupus nephritis , 2009, Nature Reviews Disease Primers.

[48]  E. Jatem,et al.  Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience , 2019, Lupus.

[49]  Z. Amoura,et al.  Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial , 2019, Annals of the rheumatic diseases.

[50]  B. Yoo,et al.  Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine , 2019, Lupus.

[51]  Paul J. Hoover,et al.  Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. , 2019, Seminars in arthritis and rheumatism.

[52]  Wenshan Lin,et al.  Multitarget Therapy: An Effective and Safe Therapeutic Regimen for Lupus Nephritis. , 2019, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[53]  B. Rovin,et al.  The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future. , 2019, Advances in chronic kidney disease.

[54]  D. W. Powell,et al.  Utilization of Biomarkers in Lupus Nephritis. , 2019, Advances in chronic kidney disease.

[55]  A. Bomback,et al.  Lupus Podocytopathy: An Overview. , 2019, Advances in chronic kidney disease.

[56]  V. D’Agati,et al.  Classification of Lupus Nephritis; Time for a Change? , 2019, Advances in chronic kidney disease.

[57]  C. Rodrigues,et al.  Outcome and Prognosis of Patients With Lupus Nephritis Submitted to Renal Transplantation , 2019, Scientific Reports.

[58]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.

[59]  T. Dörner,et al.  Novel paradigms in systemic lupus erythematosus , 2019, The Lancet.

[60]  F. Gentile,et al.  Antiphospholipid antibodies and renal transplant: A systematic review and meta-analysis. , 2019, Seminars in arthritis and rheumatism.

[61]  M. Ward,et al.  EULAR recommendations for the management of antiphospholipid syndrome in adults , 2019, Annals of the rheumatic diseases.

[62]  Debra F. Weinstein,et al.  Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. , 2019, Lancet.

[63]  M. Dall'era,et al.  Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies , 2019, Lupus.

[64]  L. Quintana,et al.  Refractory lupus nephritis: When, why and how to treat. , 2019, Autoimmunity reviews.

[65]  C. Gordon,et al.  2019 update of the EULAR recommendations for the management of systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.

[66]  R. Moots,et al.  Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis , 2019, Lupus.

[67]  M. Serrano,et al.  Antiphospholipid Syndrome and Renal Allograft Thrombosis. , 2019, Transplantation.

[68]  H. Anders,et al.  Refractory lupus nephritis: a survey , 2019, Lupus.

[69]  S. Igel,et al.  Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry , 2019, Genetics in Medicine.

[70]  David W. Johnson,et al.  Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.

[71]  E. Lewis,et al.  Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes , 2019, Arthritis & rheumatology.

[72]  Hyon K. Choi,et al.  Renal Transplantation and Survival Among Patients With Lupus Nephritis , 2019, Annals of Internal Medicine.

[73]  M. Papotti,et al.  Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study , 2018, Annals of the rheumatic diseases.

[74]  B. Rovin,et al.  B-cell therapy in lupus nephritis: an overview. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[75]  H. Nagaraja,et al.  Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. , 2019, Kidney international.

[76]  B. Rovin,et al.  A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. , 2019, Kidney international.

[77]  D. Miranda-Hernández,et al.  Renal transplantation in systemic lupus erythematosus: Comparison of graft survival with other causes of end-stage renal disease. , 2019, Reumatologia clinica.

[78]  S. Husain,et al.  The long-term outcomes and histological transformation in class II lupus nephritis , 2018, Saudi medical journal.

[79]  P. Nachman.  Repeat kidney biopsy for lupus nephritis: an important step forward. , 2018, Kidney international.

[80]  Z. Jing,et al.  Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. , 2018, Autoimmunity reviews.

[81]  H. Nagaraja,et al.  A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. , 2018, Kidney international.

[82]  A. Bomback.  Nonproliferative Forms of Lupus Nephritis: An Overview. , 2018, Rheumatic diseases clinics of North America.

[83]  G. Ruiz-Irastorza,et al.  Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions , 2018, Current opinion in rheumatology.

[84]  I. Weitz,et al.  Complement-mediated thrombotic microangiopathy associated with lupus nephritis. , 2018, Blood advances.

[85]  C. Ponticelli,et al.  Important considerations in pregnant patients with lupus nephritis , 2018, Expert review of clinical immunology.

[86]  D. Isenberg,et al.  Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis , 2018, Clinical Rheumatology.

[87]  F. Pieruzzi,et al.  Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis , 2018, Annals of the rheumatic diseases.

[88]  H. Brunner,et al.  Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. , 2018, The Journal of pediatrics.

[89]  R. Correa-Rotter,et al.  Long-term survival of kidney grafts in lupus nephritis: a Mexican cohort , 2018, Lupus.

[90]  Agnes B. Fogo,et al.  Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. , 2018, Kidney international.

[91]  C. Mok,et al.  Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort , 2018, Lupus.

[92]  Yuh-Lih Chang,et al.  Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus. , 2018, Clinical nephrology.

[93]  G. Ruiz-Irastorza,et al.  Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long‐Term Disease Control: An Observational Study , 2018, Arthritis care & research.

[94]  D. Gladman,et al.  Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis , 2018, Lupus.

[95]  Yong-Beom Park,et al.  Renal outcome after kidney-transplantation in Korean patients with lupus nephritis , 2018, Lupus.

[96]  Y. Wen,et al.  Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy , 2018, The Journal of Rheumatology.

[97]  K. Saito,et al.  Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus , 2018, Lupus.

[98]  G. Chusney,et al.  Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[99]  M. Kashgarian,et al.  Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis , 2017, Clinical kidney journal.

[100]  A. Fernández-Rodríguez,et al.  Kidney transplantation in systemic lupus erythematosus: Outcomes and prognosis. , 2018, Medicina clínica (Ed. impresa).

[101]  D. Karp,et al.  Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. , 2017, Clinical immunology.

[102]  C. Zeng,et al.  Multitarget Therapy for Maintenance Treatment of Lupus Nephritis. , 2017, Journal of the American Society of Nephrology : JASN.

[103]  C. Pusey,et al.  Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy , 2017, Kidney international.

[104]  Ming-hui Zhao,et al.  Redefining lupus nephritis: clinical implications of pathophysiologic subtypes , 2017, Nature Reviews Nephrology.

[105]  J. Nolla,et al.  The value of repeat biopsy in lupus nephritis flares , 2017, Medicine.

[106]  E. Bonfá,et al.  Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? , 2017, Lupus Science & Medicine.

[107]  B. Rovin,et al.  Update on Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[108]  A. Schwarting,et al.  Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study , 2017, Arthritis & rheumatology.

[109]  Ang Li,et al.  Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. , 2017, The Lancet. Haematology.

[110]  G. Echeverri,et al.  Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience , 2017, Lupus.

[111]  T. Imaizumi,et al.  Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy , 2017, Clinical and Experimental Nephrology.

[112]  J. Yazdany,et al.  Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence , 2017, Rheumatology International.

[113]  C. Ponticelli,et al.  Hydroxychloroquine in systemic lupus erythematosus (SLE) , 2017, Expert opinion on drug safety.

[114]  J. Yazdany,et al.  Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. , 2017, Autoimmunity reviews.

[115]  T. Cavero,et al.  Eculizumab in secondary atypical haemolytic uraemic syndrome , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[116]  B. Basu,et al.  Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis , 2017, Pediatric Nephrology.

[117]  G. Bakris,et al.  Mineralocorticoid antagonists in chronic kidney disease , 2017, Current opinion in nephrology and hypertension.

[118]  P. Ravani,et al.  Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. , 2016, Journal of autoimmunity.

[119]  David W. Johnson,et al.  Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. , 2016, Kidney international.

[120]  M. Ward,et al.  Risk of End‐Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Meta‐Analysis , 2016, Arthritis & rheumatology.

[121]  C. Gordon,et al.  Lupus nephritis management guidelines compared. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[122]  M. Marmor,et al.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.

[123]  M. Robson,et al.  Risk of clinical deterioration in patients with lupus nephritis receiving rituximab , 2016, Lupus.

[124]  A. Bomback,et al.  Lupus Podocytopathy: A Distinct Entity. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[125]  C. Zeng,et al.  Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[126]  R. Correa-Rotter,et al.  Renal flare prediction and prognosis in lupus nephritis Hispanic patients , 2016, Lupus.

[127]  R. Fischer-Betz,et al.  The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.

[128]  Caroline Gordon,et al.  The frequency and outcome of lupus nephritis: results from an international inception cohort study. , 2016, Rheumatology.

[129]  C. Gordon,et al.  BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. , 2016, Rheumatology.

[130]  D. D'cruz,et al.  Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis , 2015, Annals of the rheumatic diseases.

[131]  C. Mok,et al.  Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up , 2014, Annals of the rheumatic diseases.

[132]  A. Miller,et al.  Immunopharmacology , 2016, Springer International Publishing.

[133]  Mimi Y. Kim,et al.  Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. , 2016, American journal of obstetrics and gynecology.

[134]  D. D'cruz,et al.  Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. , 2016, Autoimmunity reviews.

[135]  E. Lazaro,et al.  Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review , 2016, Clinical Rheumatology.

[136]  B. Rovin,et al.  A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial , 2015, Lupus Science & Medicine.

[137]  V. Garovic,et al.  Pregnancy and Lupus Nephritis. , 2015, Seminars in nephrology.

[138]  D. Roccatello,et al.  Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry , 2015 .

[139]  M. Dall'era,et al.  Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome , 2015, Lupus Science & Medicine.

[140]  L. Padyukov,et al.  Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up , 2015, Arthritis Research & Therapy.

[141]  W. McClellan,et al.  Association of Time to Kidney Transplantation With Graft Failure Among US Patients With End‐Stage Renal Disease Due to Lupus Nephritis , 2015, Arthritis care & research.

[142]  H. Bao,et al.  Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study , 2015, Lupus.

[143]  S. Quaglini,et al.  The Value of a Panel of Autoantibodies for Predicting the Activity of Lupus Nephritis at Time of Renal Biopsy , 2015, Journal of immunology research.

[144]  Y. Li,et al.  Multitarget Therapy for Induction Treatment of Lupus Nephritis , 2015, Annals of Internal Medicine.

[145]  M. Marmor,et al.  The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. , 2014, JAMA ophthalmology.

[146]  D. Gladman,et al.  Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment , 2014, The Journal of Rheumatology.

[147]  Y. Lo,et al.  Outcome of lupus nephritis after entering into end-stage renal disease and comparison between different treatment modalities: a nationwide population-based cohort study in Taiwan. , 2014, Transplantation proceedings.

[148]  Y. Molad,et al.  Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study , 2014, Clinical Rheumatology.

[149]  A. Malvar,et al.  The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients , 2014, Lupus.

[150]  S. Galimberti,et al.  The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[151]  M. Hudson,et al.  Association of Smoking With Cutaneous Manifestations in Systemic Lupus Erythematosus , 2013, Arthritis care & research.

[152]  R. Fischer-Betz,et al.  Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. , 2013, Rheumatology.

[153]  V. Ruland,et al.  Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. , 2013, Autoimmunity reviews.

[154]  D. Jayne,et al.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[155]  M. Beggs,et al.  Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. , 2013, Journal of the American Society of Nephrology : JASN.

[156]  Jun Liu,et al.  Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. , 2013, Arthritis and rheumatism.

[157]  Min Chen,et al.  The spectrum of renal thrombotic microangiopathy in lupus nephritis , 2013, Arthritis Research & Therapy.

[158]  E. Ginzler,et al.  Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE , 2013, Lupus.

[159]  C. Nelson-Piercy,et al.  Pregnancy and renal outcomes in lupus nephritis: an update and guide to management , 2012, Lupus.

[160]  M. Khamashta,et al.  Glucocorticoid use and abuse in SLE. , 2012, Rheumatology.

[161]  S. Seshan,et al.  Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[162]  L. Qu,et al.  Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study , 2012, Lupus.

[163]  N. Chen,et al.  Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome , 2012, Nephrology.

[164]  R. Maciuca,et al.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. , 2012, Arthritis and rheumatism.

[165]  N. Chen,et al.  Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[166]  Deborah Levy,et al.  Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus , 2012, Arthritis care & research.

[167]  M. Clementi,et al.  Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services , 2012, American journal of medical genetics. Part A.

[168]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[169]  B. Rutkowski,et al.  Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial , 2012, International Urology and Nephrology.

[170]  D. Isenberg,et al.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. , 2011, The New England journal of medicine.

[171]  A. Doria,et al.  Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis , 2011, Lupus.

[172]  R. Stratta,et al.  Gout and transplantation: new treatment option-same old drug interaction. , 2011, Transplantation.

[173]  D. Gladman,et al.  Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. , 2011, Kidney international.

[174]  B. Chung,et al.  ORIGINAL ARTICLE DOI: 10.3904/kjim.2011.26.1.60 Comparison of Clinical Outcomes by Different Renal Replacement Therapy in Patients with End-Stage Renal Disease Secondary to Lupus Nephritis , 2022 .

[175]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[176]  Xueqing Yu,et al.  Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[177]  J. Bienvenu,et al.  Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares , 2011, Lupus.

[178]  G. Appel,et al.  Updates on the treatment of lupus nephritis. , 2010, Journal of the American Society of Nephrology : JASN.

[179]  Kenneth G. C. Smith,et al.  Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[180]  D. D'cruz,et al.  Practical management of lupus nephritis in pregnancy and the puerperium , 2010, Expert review of clinical pharmacology.

[181]  D. Jayne,et al.  What nephrologists need to know about antiphospholipid syndrome. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[182]  Z. Hrnčíř,et al.  Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study , 2010, Lupus.

[183]  F. Irshaid,et al.  The complex nature of serum C3 and C4 as biomarkers of lupus renal flare , 2010, Lupus.

[184]  Su-xia Wang,et al.  Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. , 2010, Kidney international.

[185]  V. Holers,et al.  The interrelationship of complement‐activation fragments and angiogenesis‐related factors in early pregnancy and their association with pre‐eclampsia , 2010, BJOG : an international journal of obstetrics and gynaecology.

[186]  M. García-Carrasco,et al.  Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients , 2010, Lupus.

[187]  I. Siempos,et al.  Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. , 2010, Kidney international.

[188]  D. Isenberg,et al.  Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study , 2009, Rheumatology.

[189]  Y. Levy,et al.  The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide , 2009, Annals of the rheumatic diseases.

[190]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[191]  C. Pineau,et al.  Cigarette Smoking and Cutaneous Damage in Systemic Lupus Erythematosus , 2009, The Journal of Rheumatology.

[192]  B. Rovin,et al.  Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[193]  L. Bianchi,et al.  Anti‐C1q Autoantibodies in Lupus Nephritis , 2009, Annals of the New York Academy of Sciences.

[194]  H. Hashimoto,et al.  Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study , 2009, Modern rheumatology.

[195]  J. Reveille,et al.  Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. , 2009, Arthritis and rheumatism.

[196]  D. Isenberg,et al.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[197]  G. Illei,et al.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. , 2009, Journal of the American Society of Nephrology : JASN.

[198]  M. Hernán,et al.  Prednisone, Lupus Activity, and Permanent Organ Damage , 2009, The Journal of Rheumatology.

[199]  C. Elie,et al.  Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[200]  J. Buyon,et al.  Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort , 2008, The Journal of Rheumatology.

[201]  S. Quaglini,et al.  Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis , 2008, Annals of the rheumatic diseases.

[202]  D. Marcelli,et al.  Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[203]  F. Buttgereit,et al.  Genomic and nongenomic effects of glucocorticoids , 2008, Nature Clinical Practice Rheumatology.

[204]  Zhi-Hong Liu,et al.  Successful treatment of class V+IV lupus nephritis with multitarget therapy. , 2008, Journal of the American Society of Nephrology : JASN.

[205]  G. McVeigh,et al.  A randomised interventional trial of ω-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus , 2007, Annals of the rheumatic diseases.

[206]  D. Hommes,et al.  Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists , 2007, Molecular and Cellular Endocrinology.

[207]  I. Gunnarsson,et al.  Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. , 2007, Arthritis and rheumatism.

[208]  L. Jacobsson,et al.  The role of exercise in the rehabilitation of patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome , 2007, Current opinion in rheumatology.

[209]  S. Suria,et al.  [Mycophenolate mofetil in the treatment of lupus nephritis, in patients with failure, intolerance or relapses after treatment with steroids and cyclophosphamide]. , 2007, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[210]  J. A. Pinto,et al.  Further description of early clinically silent lupus nephritis , 2006, Lupus.

[211]  Mimi Y. Kim,et al.  The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. , 2006, Arthritis and rheumatism.

[212]  S. Greco,et al.  A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[213]  G. Espinosa,et al.  Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. , 2006, Arthritis and rheumatism.

[214]  M. Amigo.  Kidney disease in antiphospholipid syndrome. , 2006, Rheumatic diseases clinics of North America.

[215]  Y. Shoenfeld,et al.  The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans , 2006, Lupus.

[216]  R. González-Amaro,et al.  Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study , 2006, Arthritis research & therapy.

[217]  E. Lewis,et al.  Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis , 2006, Lupus.

[218]  Turíbio L Barros Neto,et al.  Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[219]  Mimi Y. Kim,et al.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. , 2005, The New England journal of medicine.

[220]  M. Genovese,et al.  Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. , 2005, American journal of obstetrics and gynecology.

[221]  K. Lai,et al.  Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine , 2005, Lupus.

[222]  E. Lewis,et al.  Glomerular podocytopathy in patients with systemic lupus erythematosus. , 2004, Journal of the American Society of Nephrology : JASN.

[223]  Y. Levy,et al.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. , 2004, Arthritis and rheumatism.

[224]  H. Moutsopoulos,et al.  Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. , 2004, Arthritis and rheumatism.

[225]  J. Strain,et al.  The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. , 2004, The Journal of rheumatology.

[226]  Zeruesenay Desta,et al.  Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. , 2004, Arthritis and rheumatism.

[227]  C. Gordon,et al.  EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis , 2004, Annals of the rheumatic diseases.

[228]  D. Roth,et al.  Sequential therapies for proliferative lupus nephritis. , 2004, The New England journal of medicine.

[229]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Journal of the American Society of Nephrology : JASN.

[230]  E. Soriano,et al.  The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity Among “Hispanics” , 2004, Medicine.

[231]  S. Quaglini,et al.  Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[232]  Paolo Raggi,et al.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[233]  Richard L Street,et al.  Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[234]  D. Gladman,et al.  Accrual of organ damage over time in patients with systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[235]  C. Qualls,et al.  Cigarette smoking and disease activity in systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[236]  Y. Levy,et al.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. , 2002, Arthritis and rheumatism.

[237]  K. Chan,et al.  Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. , 2002, Arthritis and rheumatism.

[238]  C. Qualls,et al.  Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. , 2001, The Journal of rheumatology.

[239]  G. Illei,et al.  Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis , 2001, Annals of Internal Medicine.

[240]  T. Chan,et al.  Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis , 2000 .

[241]  L. Magder,et al.  Damage in systemic lupus erythematosus and its association with corticosteroids. , 2000, Arthritis and rheumatism.

[242]  D. McCauliffe,et al.  Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. , 2000, Journal of the American Academy of Dermatology.

[243]  N. K. Krane,et al.  Persistent lupus activity in end-stage renal disease. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[244]  L. Yang,et al.  Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. , 1998, British journal of rheumatology.

[245]  The Gisen Group.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.

[246]  A. Steinberg,et al.  Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis , 1996, Annals of Internal Medicine.

[247]  Mark A. Murcko,et al.  Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid , 1996, Cell.

[248]  G. Hughes,et al.  Systemic Lupus Erythematosus: Clinical and Immunologic Patterns of Disease Expression in a Cohort of 1,000 Patients , 1993 .

[249]  D. Isenberg,et al.  Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. , 1991, Annals of the rheumatic diseases.

[250]  J. Berden,et al.  Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis , 1990 .

[251]  R. Weinshilboum,et al.  Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.

[252]  W. Mccune,et al.  Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. , 1988, The New England journal of medicine.

[253]  K. E. Holley,et al.  Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. , 1978, The New England journal of medicine.

[254]  A. Steinberg,et al.  Cyclophosphamide in lupus nephritis: a controlled trial. , 1971, Annals of internal medicine.